ClinicalTrials.gg
CompletedNCT01075763REALUpdated Feb 13, 2014Results posted

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

A Phase 2 interventional study of Interferon beta-1a and Placebo in Alzheimer's Disease, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Italy. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Enrollment
153rd of 170
42 · median 328
Started
2004
the only one that year
Phase 2
36 of 206
2 open now
Registered
22nd of 206
by date

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 153rd largest by enrollment of the 170 interventional ones that give a count, is the only one that started in 2004, is one of 36 in phase 2, and was the 22nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

This was a 52-week, multicentric, phase II, pilot study conducted in 40 subjects with early-onset Alzheimer's disease (AD) to evaluate safety, tolerability and clinical efficacy of subcutaneous (sc) interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] in the treatment of AD by comparing the neuropsychological performance changes into placebo and treatment arms from screening/baseline to 52 week.

Read the detailed description

Alzheimer's disease is characterized by progressive cognitive impairment resulting from neuronal loss. The primary pathological feature of the disease is the extracellular deposition of fibrillary amyloid and its compaction into senile plaques. The senile plaque is the focus of a complex cellular reaction involving the activation of both microglia and astrocytes adjacent to the amyloid plaque. In fact, microglias are the most abundant and prominent cellular components associated with these plaques. Plaque-associated microglia exhibits a reactive or activated phenotype. Through the acquisition of a reactive phenotype, microglia responds to various stimuli, as is evident by the increased expression of numerous cell-surface molecules, including major histocompatibility complex (MHC) class-II antigens and complement receptors.

Traditionally, multiple sclerosis (MS) has been considered a "demyelinating" disease. Recent immunocytochemical studies suggest that MS may be more than a demyelinating disorder, and that even in early stages of the disease, MS pathological scenario envisages axonal damage. Interferons, the modern therapeutic strategies for the treatment of MS, are cytokines - proteins which lead to a network of signals within different cells. In the immune system, IFNs act at different levels. For example, IFNs increase the expression of MHC class II antigens and, thereby, facilitate the antigen-presenting process and the activation of lymphocytes. T-lymphocytes are important targets of IFN immunomodulation. In MS, it is believed that IFN beta suppresses the production of proinflammatory cytokines such as IFN-γ and TNF-α, and increases the production of immunosuppressive cytokines such as interleukin-4 (IL-4) and IL-10. Since the activation of microglia and astrocytes is common to both AD and MS, IFN beta could have therapeutic applications in the treatment of AD. Furthermore, recent studies have also found that through astrocyte production, IFNs promote the activation of nerve-growth factor.

OBJECTIVES

  • To evaluate safety, tolerability and clinical efficacy of IFN beta-1a (Rebif® 22 mcg, tiw) in the treatment of AD

In this study, subjects were randomized into two groups: the first group (treatment arm, n=20) received Rebif® 22 mcg tiw; the second group (placebo arm, n=20) received placebo. The treatment period was for 28 weeks and subjects were followed up to Week 52. Efficacy was determined by comparing neuropsychological performance changes into placebo and treatment arms from screening/baseline to Week 52.

On Day 1 of the study treatment period, subjects received injection training and were administered the first dose of Rebif under the supervision of the clinical personnel by subcutaneous injection tiw at approximately the same time each day preferably in the late afternoon or evening. All subjects received 28 weeks of therapy and after 24 weeks from the therapy conclusion, a termination visit was conducted.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer's
  • Dementia
  • Interferon beta-1a
  • Rebif
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged between 50 and 75 years
  • Subjects diagnosed with AD, according to the , 4th edition (DSM-IV)
  • Subjects with score of 20 to 26 (inclusive)
  • Subjects supervised by a caregiver
  • Subjects who have been given informed written consent and approval of the Local Ethical Committee

Exclusion criteria

Exclusion Criteria:

  • Subjects with constant use in the 3 months prior study enrolment of other drugs that can modify the course of the disease (e.g. statins, nonsteroidal anti-inflammatory drugs [NSAIDs] and ) or symptomatic cognitive treatments (e.g. cholinesterase inhibitors)
  • Subjects with modified Hachinski Ischemic Score ≥ 4
  • Subjects who are unable to undergo neuropsychological evaluation (including analphabetism)
  • Subjects with significant liver (, alanine aminotransferase , alkaline phosphatase > 2.0 times the [ULN] of the local laboratory, or total > 1.5 times the ULN of the local laboratory), thyroid (according to clinical judgment) or hematological dysfunctions (e.g. leucocytes ≤ 2.0 * 109/Liter [L]; ≤ 100 * 109/L; ≤ 12 gram/deciliter [g/dL] for women and ≤ 13 g/dL for men, serum albumin ≤ 3 g/dL)
  • Subjects with history (past or recurrent) of depression unresponsive to medication or past medical history of suicidal ideation
  • Subjects with severe cardiac disease (angina, congestive heart failure class 3-4 [NYHA] Functional Classification , or severe arrhythmia)
  • Subjects with epilepsy
  • Subjects with concomitant use of hypnotic, anxiolytic, antidepressant, antipsychotic, anticholinergic
  • Subjects with known allergic reactions against IFNs or other components of the applied drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Treatment arm - Rebif®

    Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)

    Drug: Interferon beta-1a

  • Placebo comparator
    Placebo arm

    Subjects in this arm received placebo

    Drug: Placebo

Interventions

  • Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)

    Also known as: Rebif®

  • DrugPlacebo

    The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way

06

What researchers measure

Primary outcomes

  1. Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score

    ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score

    ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).

    Time frame: Week 12 and 28

  2. Mini Mental Status Examination (MMSE) Score

    MMSE is a tool for screening cognitive decline associated with dementia. It is a brief examination intended to evaluate an adult participant's level of cognitive functioning. The test is performed in following areas: orientation in time and place, learning and immediate recall, mental control and concentration, short-term recall, naming ability, language expression, verbal comprehension, writing comprehension, writing ability and visual-spatial coordination. Scores range between 0 (maximum cognitive deficit) and 30 (no cognitive deficit).

    Time frame: Baseline, Week 12, 28 and 52

  3. Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score

    ADAS-NonCog is a subscale of ADAS aimed to evaluate the non-cognitive features such as mood state and behavioral changes. It takes about 10 minutes to be performed and includes 10 items: testing tearful, depressed mood, concentration/distractibility, uncooperative to testing, delusions, hallucinations, pacing, motor activity increase, tremors and appetite change. Scores range between 0 (excellent performance) and 35 (worst performance).

    Time frame: Baseline, Week 12, 28 and 52

  4. Instrumental Activities of Daily Living (IADL) Score

    IADL is used to evaluate participants with early-stage disease, both to assess level of disease and to determine participant's ability of self-care. IADL scale measures functional impact of emotional, cognitive, and physical impairments. It provides information about participants' compromising rate and care he might need. It includes 8 items: testing ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medication and ability to handle finances. Scores range between 0 (impairment) and 8 (full independence).

    Time frame: Baseline, Week 28 and 52

  5. Physical Self-Maintenance Scale (PSMS) Score

    PSMS designed as a disability measure for use in planning and evaluating treatment in elderly participants living in community or in institutions, is Guttman scale containing 6 items of self-care. The scale is based on theory that human behavior can be ordered in a hierarchy of complexity, within each category, a further hierarchy of complexity runs from basic to complex activities. It includes 6 items, testing the following areas: toilet use, eating, dressing, physical appearance, deambulation and bath. Scores range between 0 (excellent performance) and 30 (worst performance).

    Time frame: Baseline, Week 28 and 52

  6. Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score

    CIBIC-PLUS: structured instrument based on comprehensive evaluation of 3 domains: participant cognition, behavior and functioning, including assessment of daily living activities. It includes 15 items and represents assessment of skilled clinician using validated scales based on the observation at interviews conducted separately with participant and caregiver familiar with behavior of participant. According to comparison between baseline and follow-up assessments, scores can range between 1 (markedly improved) and 7 (markedly worsened), with 4 indicating no change observed between two visits.

    Time frame: Week 28 and 52

  7. Geriatric Depression Scale (GDS) Score

    The GDS consists of 30 'yes' or 'no' items aimed to assess depression. One point is assigned to each answer and the cumulative score is rated on a scoring grid. Scores are grouped as follows: 0-9 'normal', 10-19 'mildly depressed', and 20-30 'severely depressed'.

    Time frame: Baseline, Week 28 and 52

  8. Global Deterioration Scale Score

    Global deterioration scale includes seven different diagnostic stages ranging between "no cognitive deterioration" and "very serious cognitive deterioration". It investigates the cognitive impairment. Scores range between 1 (no cognitive deterioration) and 7 (very severe cognitive decline).

    Time frame: Baseline, Week 28 and 52

07

Results

Posted Apr 4, 2012

Participant flow

Participant flow — Overall Study
MilestoneRebif 22 McgPlacebo
Started2319
Completed1915
Not completed44
Withdrew: Lost to follow-up21
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryAlzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score

ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score
units on a scaleRebif 22 McgPlacebo
Baseline18.63 ± 7.8619.81 ± 6.15
Week 5220.66 ± 9.5520.33 ± 10.05
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.64
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.92
SecondaryAlzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score

ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).

Time frame:
Week 12 and 28
Reported as:
Mean · units on a scale
Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score
units on a scaleRebif 22 McgPlacebo
Week 1216.74 ± 6.9417.97 ± 6.28
Week 2818.49 ± 8.7217.55 ± 7.02
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.63
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.74
SecondaryMini Mental Status Examination (MMSE) Score

MMSE is a tool for screening cognitive decline associated with dementia. It is a brief examination intended to evaluate an adult participant's level of cognitive functioning. The test is performed in following areas: orientation in time and place, learning and immediate recall, mental control and concentration, short-term recall, naming ability, language expression, verbal comprehension, writing comprehension, writing ability and visual-spatial coordination. Scores range between 0 (maximum cognitive deficit) and 30 (no cognitive deficit).

Time frame:
Baseline, Week 12, 28 and 52
Reported as:
Mean · units on a scale
Mini Mental Status Examination (MMSE) Score
units on a scaleRebif 22 McgPlacebo
Baseline23.46 ± 2.1422.93 ± 1.79
Week 1224.50 ± 3.2224.66 ± 3.14
Week 2824.25 ± 3.3723.66 ± 4.92
Week 5222.43 ± 5.3321.98 ± 5.32
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.45
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.88
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.68
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.81
SecondaryAlzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score

ADAS-NonCog is a subscale of ADAS aimed to evaluate the non-cognitive features such as mood state and behavioral changes. It takes about 10 minutes to be performed and includes 10 items: testing tearful, depressed mood, concentration/distractibility, uncooperative to testing, delusions, hallucinations, pacing, motor activity increase, tremors and appetite change. Scores range between 0 (excellent performance) and 35 (worst performance).

Time frame:
Baseline, Week 12, 28 and 52
Reported as:
Mean · units on a scale
Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score
units on a scaleRebif 22 McgPlacebo
Baseline4.37 ± 4.136.07 ± 5.01
Week 123.53 ± 3.244.73 ± 4.27
Week 284.63 ± 4.365.20 ± 3.43
Week 525.47 ± 5.177.20 ± 6.97
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.29
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.36
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.68
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.41
SecondaryInstrumental Activities of Daily Living (IADL) Score

IADL is used to evaluate participants with early-stage disease, both to assess level of disease and to determine participant's ability of self-care. IADL scale measures functional impact of emotional, cognitive, and physical impairments. It provides information about participants' compromising rate and care he might need. It includes 8 items: testing ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medication and ability to handle finances. Scores range between 0 (impairment) and 8 (full independence).

Time frame:
Baseline, Week 28 and 52
Reported as:
Mean · units on a scale
Instrumental Activities of Daily Living (IADL) Score
units on a scaleRebif 22 McgPlacebo
Baseline6.11 ± 1.456.20 ± 1.57
Week 285.84 ± 1.175.60 ± 1.68
Week 524.89 ± 1.855.67 ± 1.63
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.86
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.62
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.21
SecondaryPhysical Self-Maintenance Scale (PSMS) Score

PSMS designed as a disability measure for use in planning and evaluating treatment in elderly participants living in community or in institutions, is Guttman scale containing 6 items of self-care. The scale is based on theory that human behavior can be ordered in a hierarchy of complexity, within each category, a further hierarchy of complexity runs from basic to complex activities. It includes 6 items, testing the following areas: toilet use, eating, dressing, physical appearance, deambulation and bath. Scores range between 0 (excellent performance) and 30 (worst performance).

Time frame:
Baseline, Week 28 and 52
Reported as:
Mean · units on a scale
Physical Self-Maintenance Scale (PSMS) Score
units on a scaleRebif 22 McgPlacebo
Baseline6.42 ± 1.026.40 ± 0.91
Week 286.74 ± 1.377.00 ± 2.65
Week 527.79 ± 3.346.87 ± 1.68
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.95
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.73
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.30
SecondaryClinician's Interview Based Impression of Change (CIBIC-PLUS) Score

CIBIC-PLUS: structured instrument based on comprehensive evaluation of 3 domains: participant cognition, behavior and functioning, including assessment of daily living activities. It includes 15 items and represents assessment of skilled clinician using validated scales based on the observation at interviews conducted separately with participant and caregiver familiar with behavior of participant. According to comparison between baseline and follow-up assessments, scores can range between 1 (markedly improved) and 7 (markedly worsened), with 4 indicating no change observed between two visits.

Time frame:
Week 28 and 52
Reported as:
Number · participants
Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score
participantsRebif 22 McgPlacebo
Week 28: CIBIC-PLUS Score 110
Week 28: CIBIC-PLUS Score 202
Week 28: CIBIC-PLUS Score 376
Week 28: CIBIC-PLUS Score 485
Week 28: CIBIC-PLUS Score 530
Week 28: CIBIC-PLUS Score 602
Week 28: CIBIC-PLUS Score 700
Week 52: CIBIC-PLUS Score 100
Week 52: CIBIC-PLUS Score 202
Week 52: CIBIC-PLUS Score 362
Week 52: CIBIC-PLUS Score 474
Week 52: CIBIC-PLUS Score 514
Week 52: CIBIC-PLUS Score 643
Week 52: CIBIC-PLUS Score 710
SecondaryGeriatric Depression Scale (GDS) Score

The GDS consists of 30 'yes' or 'no' items aimed to assess depression. One point is assigned to each answer and the cumulative score is rated on a scoring grid. Scores are grouped as follows: 0-9 'normal', 10-19 'mildly depressed', and 20-30 'severely depressed'.

Time frame:
Baseline, Week 28 and 52
Reported as:
Mean · units on a scale
Geriatric Depression Scale (GDS) Score
units on a scaleRebif 22 McgPlacebo
Baseline10.11 ± 6.1310.67 ± 6.53
Week 289.68 ± 5.749.07 ± 4.32
Week 5210.79 ± 5.937.50 ± 5.56
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.80
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.74
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.12
SecondaryGlobal Deterioration Scale Score

Global deterioration scale includes seven different diagnostic stages ranging between "no cognitive deterioration" and "very serious cognitive deterioration". It investigates the cognitive impairment. Scores range between 1 (no cognitive deterioration) and 7 (very severe cognitive decline).

Time frame:
Baseline, Week 28 and 52
Reported as:
Mean · units on a scale
Global Deterioration Scale Score
units on a scaleRebif 22 McgPlacebo
Baseline3.00 ± 0.472.87 ± 0.74
Week 283.05 ± 0.783.00 ± 0.93
Week 523.26 ± 0.813.20 ± 1.08
Statistical analysis
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.53
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.85
  • Rebif 22 Mcg vs Placebo · t-test, 2 sided · p = 0.85

Adverse events

Collected over Baseline to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif 22 Mcg—0/23 (0%)5/23 (21.7%)
Placebo—0/19 (0%)5/19 (26.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRebif 22 McgPlacebo
High CholesterolInvestigations3/230/19
Articular PainMusculoskeletal and connective tissue disorders0/232/19
High pseudocholinesteraseInvestigations2/231/19
High level of aspartate aminotransferase (AST) - alanine transaminase (ALT)Investigations0/231/19
High thyroid stimulating hormoneInvestigations0/231/19
Low blood pressureVascular disorders0/231/19
Right ear buzzingEar and labyrinth disorders0/231/19
Flu-like syndromeGeneral disorders0/231/19
FeverGeneral disorders1/230/19
High level of alanine transaminase (ALT) and aspartate aminotransferase (AST)Investigations1/230/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rebif 22 McgPlaceboTotal
Mean63.00 ± 9.0864.58 ± 6.4163.71 ± 7.87
Sex: Female, Male
Sex: Female, Male(Participants)Rebif 22 McgPlaceboTotal
Female151126
Male8816
08

Study locations

1 site
  • U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina
    Catania, CT 95122, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2010
First posted
Feb 25, 2010
Start
Nov 2004
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Apr 4, 2012
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01075763
Collaborators
Merck Serono S.P.A., Italy
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Nov 2004
Primary completion
May 2008
Completion
May 2008
Results posted
Apr 4, 2012
Last update
Feb 13, 2014

Study contacts

Andrea Paolillo, MD, PhD
study director · Merck Serono S.P.A., Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion